Dr. Emily Kathleen Curran, MD

Dr. Curran practices at UC Medical Center in Cincinnati, Ohio.

Dr. Curran's NPI, 1093978561, was assigned on July 5, 2008. Dr. Curran graduated from Stanford University School of Medicine in 2008. Dr. Curran holds Illinois license 036127842.

Dr. Curran's primary practice is UC Medical Center, at 3188 Bellevue Ave, Cincinnati, OH 45219 in Hamilton County. The practice phone is (513) 584-1000.

Dr. Curran's primary practice is UC Medical Center in Cincinnati, Ohio. Dr. Curran is also affiliated with University of Cincinnati Medical Center. The medical group on file is Cincinnati Children's. Dmand AI also links Dr. Curran to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Curran practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Curran's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Curran is board certified in hematology by the American Board of Internal Medicine. Dr. Curran is licensed in Illinois.

CMS data shows 348 Medicare services from Dr. Curran across 6 procedure codes in 2024, for 76 Medicare patients. Medicare paid $19,922 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 76 Medicare patients who saw Dr. Curran in 2024. The largest group is 65 to 74, with 35 patients. 75% of them have high blood pressure, and 74% have high cholesterol. Their average risk score is 3.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Curran's median patient age at 64, with 43% women.

In 2024, Dr. Curran wrote 139 Medicare Part D claims for 35 patients. 55% of them were for generic drugs. CMS names the drug for 43 of them, across 3 drugs with 11 or more claims each, at $293,752 in total drug cost. In 2023, CMS named 89 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Curran for performance year 2024, reported as part of a group. Dr. Curran accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 37 papers to Dr. Curran, published from 2013 to 2025. 2020 was the busiest year, with 4. The most frequent topics are Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation and Antibodies, Bispecific. Dr. Curran has published most often in Hematology Am Soc Hematol Educ Program. Dr. Curran's most frequent co-authors are Anjali S. Advani, MD, Ehab L. Atallah, MD and Talha Badar, MD.

Dmand AI links Dr. Curran to 10 clinical trials, 4 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Burkitt Lymphoma, Leukemia, Myeloid, Chronic-Phase and Precursor Cell Lymphoblastic Leukemia-Lymphoma.

CMS Open Payments shows 47 general payments to Dr. Curran from 12 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 73% of the total. Servier Pharmaceuticals LLC paid the most, $19,542.

Dr. Curran graduated from Stanford University School of Medicine in 2008.